PMID- 22511634
OWN - NLM
STAT- MEDLINE
DCOM- 20120816
LR  - 20240404
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 53
IP  - 7
DP  - 2012 Jun 5
TI  - Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ 
      hybridization and single-nucleotide polymorphism array.
PG  - 3331-9
LID - 10.1167/iovs.11-9027 [doi]
AB  - PURPOSE: To compare fluorescence in situ hybridization (FISH) using a centromeric 
      probe for chromosome 3 (CEP3) and 3p26 locus-specific probe with 
      single-nucleotide polymorphism array (SNP-A) analysis in the detection of 
      high-risk uveal melanoma. METHODS: Fifty cases of uveal melanoma (28 males, 22 
      females) treated by enucleation between 2004 and 2010 were analyzed. Fresh tissue 
      was used for FISH and SNP-A analysis. FISH was performed using a CEP3 and a 3p26 
      locus-specific probe. Tumor size, location, and clinical outcome were recorded 
      during the 7-year study period (median follow-up: 35.5 months; mean: 38.5 
      months). The sensitivity, specificity, positive predictive value, and negative 
      predictive value were calculated. RESULTS: Monosomy 3 was detected by FISH-CEP3 
      in 27 tumors (54%), FISH-3p26 deletion was found in 30 (60%), and SNP-A analysis 
      identified 31 (62%) of the tumors with monosomy 3. Due to technical failures, 
      FISH and SNP-A were noninterpretable in one case (2%) and two cases (4%), 
      respectively. In both cases of SNP-A failure, tumors were positive for FISH 3p26 
      deletion and in a single case of FISH failure, monosomy 3 was found using SNP-A. 
      No statistically significant differences were observed in any of the sensitivity 
      or specificity measures. CONCLUSIONS: For prediction of survival at 36 months, 
      FISH CEP3, FISH 3p26, and SNP-A were comparable. A combination of prognostication 
      techniques should be used in an unlikely event of technical failure (2%-4%).
FAU - Singh, Arun D
AU  - Singh AD
AD  - Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, 
      Cleveland, Ohio 44195, USA. singha@ccf.org
FAU - Aronow, Mary E
AU  - Aronow ME
FAU - Sun, Yang
AU  - Sun Y
FAU - Bebek, Gurkan
AU  - Bebek G
FAU - Saunthararajah, Yogen
AU  - Saunthararajah Y
FAU - Schoenfield, Lynn R
AU  - Schoenfield LR
FAU - Biscotti, Charles V
AU  - Biscotti CV
FAU - Tubbs, Raymond R
AU  - Tubbs RR
FAU - Triozzi, Pierre L
AU  - Triozzi PL
FAU - Eng, Charis
AU  - Eng C
LA  - eng
GR  - R01 CA136776/CA/NCI NIH HHS/United States
GR  - R01CA136776/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120605
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - Chromosome 3, monosomy 3p
RN  - Uveal melanoma
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 3/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Melanoma/*diagnosis/genetics/metabolism
MH  - Middle Aged
MH  - *Polymorphism, Single Nucleotide
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Uveal Neoplasms/*diagnosis/genetics/metabolism
MH  - Young Adult
PMC - PMC4625803
COIS- Disclosure: A.D. Singh, None; M.E. Aronow, None; Y. Sun, None; G. Bebek, None; Y. 
      Saunthararajah, None; L.R. Schoenfield, None; C.V. Biscotti, None; R.R. Tubbs, 
      None; P.L. Triozzi, None; C. Eng, None
EDAT- 2012/04/19 06:00
MHDA- 2012/08/17 06:00
PMCR- 2012/12/01
CRDT- 2012/04/19 06:00
PHST- 2012/04/19 06:00 [entrez]
PHST- 2012/04/19 06:00 [pubmed]
PHST- 2012/08/17 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - iovs.11-9027 [pii]
AID - 10.1167/iovs.11-9027 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2012 Jun 5;53(7):3331-9. doi: 10.1167/iovs.11-9027.